Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Doses First mCRC Patient in the Phase 1 alloSHRINK Trial Evaluating Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101

Celyad Announces Third Quarter 2018 Business Update

Celyad Announces Third Quarter 2018 Business Update

Celyad to Participate at Upcoming Healthcare Conferences

Celyad to Participate at Upcoming Healthcare Conferences

Discover our news

Upcoming events

Discover all events

Press material

Dear Journalists,
Please find here all information background and material for your articles.
For any media request, please refer to the contacts below.
Join our press list
Press kit

Press kit

2.4 Mo

a

Press contacts

Celyad

Nicolas Van Hoecke Director, Investor Relations & Communications

+32 (0)10 39 41 84

LifeSci Advisors

Matt Middleman

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91